Literature DB >> 27041934

Molecular aspects of prostate cancer with neuroendocrine differentiation.

Qi Li1, Connie S Zhang1, Yifen Zhang1.   

Abstract

Neuroendocrine differentiation (NED), which is not uncommon in prostate cancer, is increases in prostate cancer after androgen-deprivation therapy (ADT) and generally appears in castration-resistant prostate cancer (CRPC). Neuroendocrine cells, which are found in normal prostate tissue, are a small subset of cells and have unique function in regulating the growth of prostate cells. Prostate cancer with NED includes different types of tumor, including focal NED, pure neuroendocrine tumor or mixed neuroendocrine-adenocarcinoma. Although more and more studies are carried out on NED in prostate cancer, the molecular components that are involved in NED are still poorly elucidated. We review neuroendocrine cells in normal prostate tissue, NED in prostate cancer, terminology of NED and biomarkers used for detecting NED in routine pathological practice. Some recently reported molecular components which drive NED in prostate cancer are listed in the review.

Entities:  

Keywords:  Prostate cancer; molecular components; neuroendocrine differentiation (NED)

Year:  2016        PMID: 27041934      PMCID: PMC4779763          DOI: 10.3978/j.issn.1000-9604.2016.01.02

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  67 in total

1.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.

Authors:  Veit J Scheble; Martin Braun; Rameen Beroukhim; Craig H Mermel; Christian Ruiz; Theresia Wilbertz; Ann-Cathrin Stiedl; Karen Petersen; Markus Reischl; Rainer Kuefer; David Schilling; Falko Fend; Glen Kristiansen; Matthew Meyerson; Mark A Rubin; Lukas Bubendorf; Sven Perner
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

2.  Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Authors:  Yixuan Gong; Uma D Chippada-Venkata; Matthew D Galsky; Jiaoti Huang; William K Oh
Journal:  Prostate       Date:  2015-01-05       Impact factor: 4.104

3.  Regional distribution of neuroendocrine cells in the urogenital duct system of the male rat.

Authors:  Gerhard Aumüller; Andreas Doll; Gunther Wennemuth; Nishtman Dizeyi; Per-Anders Abrahamsson; Beate Wilhelm
Journal:  Prostate       Date:  2011-06-10       Impact factor: 4.104

Review 4.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.

Authors:  Nadezda Vashchenko; Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2005-02       Impact factor: 20.096

Review 5.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes.

Authors:  C J Schoenherr; D J Anderson
Journal:  Science       Date:  1995-03-03       Impact factor: 47.728

7.  The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.

Authors:  S Y Nakada; P A di Sant'Agnese; R A Moynes; R A Hiipakka; S Liao; A T Cockett; P A Abrahamsson
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

8.  Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.

Authors:  Alessandro Sciarra; Franco Di Silverio; Ana Maria Autran; Stefano Salciccia; Alessandro Gentilucci; Andrea Alfarone; Vincenzo Gentile
Journal:  Urol Int       Date:  2009-03-19       Impact factor: 2.089

9.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

10.  Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma.

Authors:  John M Maris
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

View more
  8 in total

1.  Role and underlying mechanisms of the interstitial protein periostin in the diagnosis and treatment of malignant tumors.

Authors:  Dong Ye; Zhi Sen Shen; Shi Jie Qiu; Qun Li; Guo Li Wang
Journal:  Oncol Lett       Date:  2017-09-01       Impact factor: 2.967

Review 2.  Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer.

Authors:  Eliane Gouvêa de Oliveira Barros; Nathalia Meireles Da Costa; Celia Yelimar Palmero; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti; Antonio Palumbo
Journal:  World J Urol       Date:  2018-07-06       Impact factor: 4.226

3.  Tumor suppression effect of targeting periostin with siRNA in a nude mouse model of human laryngeal squamous cell carcinoma.

Authors:  Dong Ye; Chongchang Zhou; Sijia Wang; Hongxia Deng; Zhisen Shen
Journal:  J Clin Lab Anal       Date:  2018-07-05       Impact factor: 2.352

Review 4.  Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.

Authors:  Dmitry S Mikhaylenko; Gennady D Efremov; Vladimir V Strelnikov; Dmitry V Zaletaev; Boris Y Alekseev
Journal:  Curr Genomics       Date:  2017-06       Impact factor: 2.236

5.  Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.

Authors:  Karin Purshouse; Anna Schuh; Benjamin P Fairfax; Sam Knight; Pavlos Antoniou; Helene Dreau; Niko Popitsch; Kevin Gatter; Ian Roberts; Lisa Browning; Zoe Traill; David Kerr; Clare Verrill; Mark Tuthill; Jenny C Taylor; Andrew Protheroe
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-05

6.  A rare case of prostate neuroendocrine tumor: A case report.

Authors:  Shunxing Teh; Fam Xeng Inn; Iqbal Hussain Rizuana; Wan Muhaizan Wm
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

7.  Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review.

Authors:  Jill B Feffer; Natalia M Branis; Jeanine B Albu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

8.  Investigation of Neural Microenvironment in Prostate Cancer in Context of Neural Density, Perineural Invasion, and Neuroendocrine Profile of Tumors.

Authors:  Dawid Sigorski; Jacek Gulczyński; Aleksandra Sejda; Wojciech Rogowski; Ewa Iżycka-Świeszewska
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.